GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (HKSE:02126) » Definitions » Debt-to-Revenue

JW (Cayman) Therapeutics Co (HKSE:02126) Debt-to-Revenue : 2.19 (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is JW (Cayman) Therapeutics Co Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

JW (Cayman) Therapeutics Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$221.9 Mil. JW (Cayman) Therapeutics Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$187.8 Mil. JW (Cayman) Therapeutics Co's annualized Revenue for the quarter that ended in Jun. 2024 was HK$186.9 Mil. JW (Cayman) Therapeutics Co's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 was 2.19.

JW (Cayman) Therapeutics Co Debt-to-Revenue Historical Data

The historical data trend for JW (Cayman) Therapeutics Co's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW (Cayman) Therapeutics Co Debt-to-Revenue Chart

JW (Cayman) Therapeutics Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial N/A N/A 4.77 1.92 1.83

JW (Cayman) Therapeutics Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.14 1.75 2.23 1.85 2.19

Competitive Comparison of JW (Cayman) Therapeutics Co's Debt-to-Revenue

For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

JW (Cayman) Therapeutics Co's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where JW (Cayman) Therapeutics Co's Debt-to-Revenue falls into.


JW (Cayman) Therapeutics Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

JW (Cayman) Therapeutics Co's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(132.353 + 216.339) / 190.16
=1.83

JW (Cayman) Therapeutics Co's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(221.857 + 187.804) / 186.92
=2.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2024) Revenue data.

JW (Cayman) Therapeutics Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

JW (Cayman) Therapeutics Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (HKSE:02126) » Definitions » Debt-to-Revenue
Comparable Companies
HKSE:02197 HKSE:02185 HKSE:06996 HKSE:06998 HKSE:03681 HKSE:01228 HKSE:02142 HKSE:09939 HKSE:01875 HKSE:00690 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
JWCTF:USA JNY:Germany
Address
No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN
Website
https://www.jwtherapeutics.com
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
Executives
Li Dan 2202 Interest of your spouse
Li Yiping James 2201 Interest of corporation controlled by you
Syracuse Biopharma (cayman) Ii, Ltd. 2501 Other
Bristol-myers Squibb Company 2201 Interest of corporation controlled by you
Celgene Corporation 2201 Interest of corporation controlled by you
Juno Therapeutics, Inc. 2101 Beneficial owner
Syracuse Biopharma (cayman) Ltd. 2501 Other

JW (Cayman) Therapeutics Co Headlines

No Headlines